Prior therapies have focused on effects, not on causes. They have tried to help symptoms or wished to remove amyloid or tau proteins.
Research shows that cell aging triggers the gradual accumulation of amyloid, as well as the loss of neurons that defines Alzheimer’s.
Telomerase resets the abnormal pattern of gene expression that results in Alzheimer’s disease. We can make a difference. Join us.
This is Iris, the mother of our CEO and catalyst for the founding of Telocyte.
We would like to acknowledge the wonderful care and support for Iris
provided by the staff and friends at The Foundation of Lady Katherine Leveson, Temple Balsall, in the UK.
Farewell Iris, you always lead by example, facing adversity with good humour and a resolve to overcome.
As a dedicated nurse, she helped many during her life, her simple request to us was that we should find
a future beyond Alzheimer’s for others.
That is our intention.
Dr. Fossel is the driving force behind Telocyte and has been the leader in proposing the use of telomerase to treat human disease for the past two decades.
Peter T. Rayson is an experienced industry executive who provides leadership and business acumen for Telocyte.
Telocyte and CNIO will be collaborating to take Telomerase Therapy to FDA human trials.
Under the direction of Dr. Maria Blasco, C.N.I.O. – The Spanish National Research Centre, has recently made advances in both animal research and delivery systems that has facilitated an opportunity to pursue unsurpassed clinical advances in the field of telomerase therapy. Dr. Blasco is an internationally recognized expert in the field of telomerase
In 2014, Dr. Fossel gave this short (17-minute) talk at IdeaCity, giving a clear and concise presentation of the rationale for and the history of telomerase therapy, as well as the plans for human trials.